Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

Cigna Switch Program Intensifies Competitive Dynamics For Cosentyx

A new pilot program by the insurer is offering a $500 debit card to patients who switch from the blockbuster Novartis psoriasis drug to Lilly's rival Taltz or other preferred drugs.

Market Access Pricing Strategies

Lilly’s Bio-Medicines Portfolio Grows To Offset Pressures In Key Markets

Lilly Bio-Medicines president Ilya Yuffa oversees newer products in competitive therapeutic areas and drug classes, but additional indications and new therapies within the group’s immunology, pain and neuroscience focus areas will capitalize on the group’s existing commercial expertise. 

Business Strategies Launches

Novartis Steers Zolgensma Towards Commercial Success In Europe

The head of Novartis Gene Therapies in Europe tells Scrip that innovative payment models and involving all stakeholders have helped payers see beyond a simple price tag and see the benefits of a one-time gene therapy for spinal muscular atrophy.

Pricing Strategies Gene Therapy

Jyseleca European Launches Could Lift Gloom At Galapagos

The Belgian biotech is pleased with the launch of its rheumatoid arthritis drug in Germany and the Netherlands and it has also secured a broad label from NICE.

Launches Immune Disorders

Novartis and Gates Foundation Ink Sickle Cell Gene Therapy Pact

The Swiss major envisions developing an accessible in vivo gene therapy for SCD that could potentially be administered once directly to the patient without the need to modify cells in a lab.

Gene Therapy Blood & Coagulation Disorders

US Prescribers Embrace Oncology Biosimilars; How Will Humira Follow-Ons Fare?

Rheumatologists may be more cautious about prescribing biosimilars to Humira than they have been for biosimilars to Avastin and Herceptin. But pharmacy benefit managers will have more influence over Humira biosimilars, which adds a new dynamic to the follow-on market.

Biosimilars Market Access

Biocon-CHAI Cancer Biosimilars Deal Promises Large Savings

Biocon Biologics strikes deal with the Clinton Health Access Initiative to provide cost-effective alternatives to pricey reference biologics, beginning with trastuzumab and pegfilgrastim. Savings of over 59% for buyers are expected in some cases.

Commercial Cancer

More Big Pharma Players Have Access Plans For Poorer Countries

The notion that pharma R&D caters for western populations first and only much later are the fruits of that research made available for low-income countries is slowly but surely changing, according to a high-profile review of access to drugs.

Market Access Research and Development Strategies

Europe Takes Leap Of Faith On AstraZeneca Vaccine

A conditional marketing authorization for AstraZeneca/Oxford's COVID-19 vaccine came just hours after the European Medicines Agency’s CHMP voted unanimously to recommend it on Friday.

Approvals Coronavirus COVID-19
See All
UsernamePublicRestriction

Register